Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenosine-2,3-dialdehyde, commonly referred to as AdOx, is a potent and irreversible inhibitor of S-adenosylhomocysteine (SAH) hydrolase (adenosylhomocysteinase). By blocking the activity of SAH hydrolase, AdOx prevents the breakdown of SAH into adenosine and homocysteine, leading to a significant intracellular accumulation of SAH. Because SAH is a powerful competitive inhibitor of S-adenosylmethionine (SAM)-dependent methyltransferases, its buildup results in the broad suppression of biological methylation processes, including the methylation of DNA, RNA, and proteins. In biomedical research, AdOx is extensively utilized as a pharmacological tool to study the regulatory roles of methylation in diverse cellular processes such as T-cell activation, viral replication, and epigenetic gene regulation. It is primarily characterized as a research reagent and has not been developed for clinical therapeutic use in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenosine-2,3-dialdehyde.